Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?

Dogansen S. C., Selcukbiricik Ö., Tanrikulu S., Yarman S.

Pituitary, cilt.19, sa.3, ss.303-10, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1007/s11102-016-0708-3
  • Dergi Adı: Pituitary
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.303-10
  • Anahtar Kelimeler: Prolactinoma, Dopamine agonist withdrawal, Cabergoline, Bromocriptine, Recurrence, LONG-TERM THERAPY, BROMOCRIPTINE TREATMENT, 2ND ATTEMPT, FOLLOW-UP, CABERGOLINE, HYPERPROLACTINEMIA, RECURRENCE, REMISSION, MICROPROLACTINOMAS, MACROPROLACTINOMAS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma.